Skip to content
Home  /  RCPA Haematology  /  Study notes  /  BCR-ABL1 IS Quantification: Principles and Techniques of PCR for CML Monitoring

BCR-ABL1 IS Quantification: Principles and Techniques of PCR for CML Monitoring

● RCPA Haematology LO RCPAHAEM_GEN_010 2,611 words
Free preview. This study note covers learning objective RCPAHAEM_GEN_010 from the RCPA Haematology curriculum. Inside PRIMEX you get AI-graded SAQ practice on this topic, voice viva with the AI examiner, MCQs across the full syllabus, and a curriculum tracker that ticks off every learning objective.

Overview

The principles underlying PCR technology include the thermocycling reaction, exponential amplification kinetics, real-time fluorescent detection, normalisation to a reference gene, and conversion to IS values; they inform both the interpretation of clinical results and the limitations of the technique.


Molecular Biology of BCR-ABL1 Transcripts

Breakpoint Regions and Fusion Transcript Types

The reciprocal translocation t(9;22)(q34.12;q11.23) juxtaposes the ABL1 proto-oncogene from chromosome 9 to the BCR gene on chromosome 22, generating the Philadelphia (Ph) chromosome. Depending on the precise BCR breakpoint location, distinct fusion transcripts are produced:

Transcript BCR Breakpoint Region Protein Predominant Disease Association
e13a2 (b2a2) Major BCR (M-BCR) p210 Typical CML, some Ph+ ALL
e14a2 (b3a2) Major BCR (M-BCR) p210 Typical CML (most common)
e1a2 Minor BCR (m-BCR) p190 Ph+ B-ALL, rare CML
e19a2 Micro-BCR (μ-BCR) p230 Neutrophilic CML (more indolent)
e13a3 / e14a3 M-BCR (atypical ABL1 breakpoint) p210 Rare; not detected by standard qPCR

Principles of Polymerase Chain Reaction

Basic PCR Mechanism

PCR is an in vitro enzymatic method for exponential amplification of a defined DNA sequence. Each cycle consists of three temperature-dependent steps:

  1. Denaturation (~94-96°C): Heat disrupts hydrogen bonds, separating double-stranded DNA (or cDNA) into single strands.
  2. Annealing (~50-65°C): Short synthetic oligonucleotide primers complementary to sequences flanking the target region bind to their respective single-stranded templates.
  3. Extension (~72°C): A thermostable DNA polymerase (most commonly Taq polymerase, derived from Thermus aquaticus) extends the primers in the 5′→3′ direction using deoxynucleotide triphosphates (dNTPs), synthesising new complementary strands.

After $n$ cycles of amplification, the theoretical yield is $2^n$ copies of the target sequence, producing exponential amplification.

Reverse Transcription, From RNA to cDNA

BCR-ABL1 is detected at the mRNA level because:


Real-Time Quantitative PCR (RQ-PCR): Principles

Exponential Kinetics and the Quantification Cycle

The critical concept is the quantification cycle (Cq), formerly termed Ct (threshold cycle): the cycle number at which fluorescence crosses a defined threshold above background noise. Because amplification is exponential in the early cycles, the Cq is inversely proportional to the starting quantity of target template:

$$\text{Cq} \propto -\log_2(\text{initial template quantity})$$

Fluorescent Detection Strategies

Method Principle Specificity
TaqMan (hydrolysis) probes Dual-labelled probe (5′ reporter fluorophore + 3′ quencher) hybridises within the amplicon; 5′→3′ exonuclease activity of Taq separates reporter from quencher, generating signal proportional to amplicon accumulation High, sequence-specific
SYBR Green Intercalating dye fluoresces when bound to any double-stranded DNA Lower, detects all dsDNA including primer-dimers

Normalisation to a Reference Gene

Validated reference genes for CML monitoring (Europe Against Cancer programme):

Reference Gene Notes
ABL1 Most widely used; recommended by ELN
GUSB (beta-glucuronidase) Validated alternative
B2M (beta-2-microglobulin) Validated alternative

The ideal reference gene must:

The BCR-ABL1 transcript level is expressed as a ratio relative to the reference gene:

$$\text{BCR-ABL1\%} = \frac{\text{BCR-ABL1 copies}}{\text{ABL1 copies}} \times 100\%$$

Copy numbers are derived from Cq values using a standard curve or efficiency-corrected calculation.


The International Scale (IS)

Rationale for Standardisation

The International Scale (IS) harmonises results globally by defining a common zero point:

Conversion Factors

Each laboratory must determine its own laboratory-specific conversion factor (CF) by comparing raw ratio results against a certified reference material or by direct comparison with a reference laboratory using split samples:

$$\text{BCR-ABL1\%}^{\text{IS}} = \text{BCR-ABL1\%}^{\text{local}} \times CF$$


Molecular Response Milestones on the IS

Response Level BCR-ABL1% IS Log Reduction from Baseline Approximate Cytogenetic Correlate
Partial cytogenetic response (PCyR) ~≤10% IS ~1-log 1-35% Ph+ metaphases
Complete cytogenetic response (CCyR) ~≤1% IS ~2-log 0% Ph+ metaphases
MMR (MR3) ≤0.1% IS ≥3-log -
MR4 ≤0.01% IS ≥4-log -
MR4.5 ≤0.0032% IS ≥4.5-log -
MR5 ≤0.001% IS ≥5-log -

Prognostic significance of molecular milestones (IRIS data): CCyR plus MMR at 12 months was associated with 97% progression-free survival at 5 years, compared with 89% for CCyR without MMR.

ELN 2020 Molecular Response Milestones for TKI Therapy

Time Point Optimal Warning Failure
3 months BCR-ABL1 ≤10% IS - BCR-ABL1 >10% IS (confirmed within 1-3 months)
6 months BCR-ABL1 ≤1% IS BCR-ABL1 >1-10% IS BCR-ABL1 >10% IS
12 months BCR-ABL1 ≤0.1% IS BCR-ABL1 >0.1-1% IS BCR-ABL1 >1% IS
Any time thereafter BCR-ABL1 ≤0.1% IS >0.1-1% IS, or loss of MMR in patients who discontinued TKI >1% IS, resistance mutations, high-risk CCA in Ph+ cells

The 3-month BCR-ABL1 IS result is the single most powerful early predictor of long-term outcome in patients on TKI therapy.


Assay Design and Technical Considerations

Duplex vs. Singleplex Reactions

Sensitivity and Adequacy Criteria

A well-validated RQ-PCR assay should achieve:

When ABL1 copy numbers fall below the minimum adequacy threshold, indicating insufficient RNA quality or input, the result must be reported as inadequate rather than undetectable, to avoid false-negative conclusions.

Blood vs. Bone Marrow


Digital PCR: An Emerging Quantification Method

Absolute quantification is achieved by Poisson statistical modelling without a standard curve:

$$\lambda = -\ln(1 - p)$$

where $\lambda$ is the average number of target molecules per partition and $p$ is the proportion of positive partitions.

Feature RQ-PCR Digital PCR
Quantification method Relative (standard curve / CF required) Absolute (Poisson statistics; no standard curve)
Inter-laboratory harmonisation Requires IS conversion factor Potentially reduced reliance on CF
Precision at low copy number Limited Superior
Current clinical status Standard of care Investigational; not yet routine standard

Digital PCR is an area of active investigation and may complement or eventually supplant RQ-PCR for deep molecular response assessment and treatment-free remission (TFR) monitoring.


Qualitative PCR: Role and Limitations

Qualitative (Endpoint) RT-PCR

Qualitative multiplex RT-PCR is used primarily to:

  1. Confirm the BCR-ABL1 fusion transcript type at diagnosis, particularly in Ph-negative patients, and to detect rare/atypical transcripts not covered by standard qPCR
  2. Screen for BCR-ABL1 in suspected CML where karyotype and FISH are negative

Nested PCR


BCR-ABL1 Kinase Domain Mutation Analysis

Rising BCR-ABL1 IS levels may indicate the emergence of BCR-ABL1 kinase domain (KD) mutations conferring TKI resistance. Mutation analysis is indicated when:

Method Analytical Sensitivity Key Feature
Sanger sequencing of RT-PCR amplicons ~20% Detects all mutations; misses low-level clones
Next-generation sequencing (NGS) ~1-5% Preferred; detects compound/low-level mutations
Allele-specific oligonucleotide PCR (ASO-PCR) ~0.1% High sensitivity for specific mutations (e.g. T315I)

Practical Monitoring Schedule and Reporting

Testing frequency:

Each report should include:


Summary of Key Concepts

Concept Key Point
Transcript type identification Mandatory at diagnosis using qualitative multiplex RT-PCR; determines suitability of standard qPCR for follow-up
Standard qPCR blind spots Does not detect e1a2, e19a2, e13a3, e14a3, or other atypical transcripts
Reference gene ABL1 preferred; normalises for RNA input variation; GUSB and B2M are validated alternatives
International Scale Anchored to IRIS median baseline (IS 100%); enables inter-laboratory comparison
Conversion factor Laboratory-specific; validated against WHO reference materials
MMR (MR3) BCR-ABL1 ≤0.1% IS; ≥3-log reduction from IS baseline
MR4.5 BCR-ABL1 ≤0.0032% IS; threshold for TFR eligibility
CCyR BCR-ABL1 ~≤1% IS; may still harbour up to $10^{10}$ leukaemic cells
3-month milestone BCR-ABL1 >10% IS (confirmed) = treatment failure; strongest early predictor of outcome
Adequacy threshold ≥32,000 ABL1 copies required; below threshold → report as inadequate, not undetectable
Digital PCR Absolute quantification without standard curve; not yet standard of care
KD mutation analysis Indicated for rising BCR-ABL1 IS or treatment failure; NGS preferred; T315I → ponatinib/asciminib
PRIMEX

Practice this topic in the app

Attempt a graded SAQ on this exact LO, run a voice viva with the AI examiner, or work through MCQs that map to RCPAHAEM_GEN_010. Your free trial covers all 26 exams.

Start 7-day free trial

7-day free trial · Cancel anytime

Start free trial→